menu search

Iq-ai higlights use of subsidiary's software in brain cancer study

IQ-AI has highlighted a new study into a rare form of brain cancer that used subsidiary Imaging  Biometric's dynamic susceptibility contrast (DSC) ma...

October 18, 2023, 11:01 am

Why shares of day one pharmaceuticals are up monday

Day One has begun a rolling NDA for its candidate DAY101 as a monotherapy for relapsed or progressive pediatric low-grade ...

June 5, 2023, 12:30 pm

Day one biopharmaceuticals shares jump 23% on positive results for glioma treatment

Day One Biopharmaceuticals DAWN, -0.37% shares climbed 23% in premarket trading Monday after the company shared new data on tovorafenib, an investigat...

June 5, 2023, 8:09 am

Day one announces new firefly-1 data for tovorafenib (day101) and initiation of rolling nda submission to fda for relapsed or progressive pediatric low-grade glioma

Overall response rate (ORR) of 67% and clinical benefit rate (CBR) of 93% in 69 heavily pretreated RANO-HGG evaluable patients The Company expects to ...

June 4, 2023, 4:45 pm

Day one announces abstracts accepted for presentation at the 2023 american society of clinical oncology (asco) annual meeting

New clinical data from registrational FIREFLY-1 study to be featured as an oral presentation Trial-in-progress poster from FIREFLY-2 and healthcare re...

April 26, 2023, 1:31 pm

In8bio stock price falls even as company receives fda orphan drug status for brain cancer treatment

IN8bio (NASDAQ:INAB), Inc shares slid 16% to $2.51 in early Tuesday trading after the biopharmaceutical company announced that it has received orphan ...

April 25, 2023, 10:40 am

Day one biopharmaceuticals: strong potential, price drop opportunity, some concerns

Day One Biopharmaceuticals is looking to file an NDA after successful glioma data. DAWN is well-finance...

April 7, 2023, 7:37 am

Day one reports fourth quarter and full year 2022 financial results and corporate progress

First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with...

March 6, 2023, 9:30 pm

Day one announces topline data from pivotal phase 2 firefly-1 trial demonstrating meaningful responses with tovorafenib (day101) in recurrent or progressive pediatric low-grade glioma

Overall response rate (ORR) of 64% and clinical benefit rate (CBR) of 91% in 69 heavily-pretreated, RANO-evaluable patients Median duration of 8.4 mon...

January 8, 2023, 10:00 pm

Day one biopharmaceuticals: recent strong data, and major catalysts ahead

Day One Biopharmaceuticals declared strong data in relapsed glioma in June. The company has strong cash...

September 4, 2022, 12:17 pm

Chimerix: advancement for rare brain cancer drug targeting specific mutation

Initiation of phase 3 ACTION study using ONC201 for treatment of glioma patients who harbor the H3 K27M...

August 23, 2022, 4:52 pm

Midatech pharma boosted by european news on key product

Midatech Pharma PLC (AIM:MTPH) is in demand after a positive European approval for a key product. The biotechnology company said that the European Me...

June 21, 2022, 4:01 am


Search within

Pages Search Results: